de novo vs in de novo

The correct phrase is "de novo." Adding "in" before "de novo" is not necessary and is not commonly used in English.

Last updated: March 24, 2024 • 790 views

This phrase is correct and commonly used in English.

"de novo"

Use "de novo" to indicate something is done anew or from the beginning.

Examples:

The case was heard de novo by the appeals court.
The experiment had to be conducted de novo due to errors in the previous attempt.

Show examples from the web [+]

Paediatrics The pharmacokinetics of basiliximab were assessed in 39 paediatric de novo renal transplantation patients.
One (1) additional low-titre de novo inhibitor was observed.
This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.
This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.
Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with de novo acute myeloid leukaemia (see section 5.1).
The safety and efficacy of Neulasta administration in de novo AML patients aged < 55 years with cytogenetics t(15; 17) have not been established.
Renal function was not better in the treatment arms with de novo Rapamune without a calcineurin inhibitor.
However, the termination of an existing supply arrangement is more likely to be found to be abusive than a de novo refusal to supply.
In de novo kidney and liver transplant patients AUC0-24 of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for Prograf at equivalent doses.
The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant recipients.
The Committee for Medicinal Products for Human Use (CHMP) decided that Simulect's benefits are greater than its risks for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients.
Simulect is indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients (1-17 years) (see section 4.2).
Clinical studies The efficacy of basiliximab in prophylaxis of organ rejection in de novo renal transplantation has been demonstrated in double-blind placebo-controlled studies.
Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.
Induction therapy (de novo Ph+ ALL)
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8; 21), t(15; 17), and inv(16)] have not been established.
Results from clinical trials performed with once-daily tacrolimus Advagraf Liver transplantation The efficacy and safety of Advagraf and Prograf, both in combination with corticosteroids, was compared in 471 de novo liver transplant recipients.
Kidney transplantation The efficacy and safety of Advagraf and Prograf, both in combination with mycophenolate mofetil (MMF) and corticosteroids, was compared in 667 de novo kidney transplant recipients.
ed The safety and efficacy of Neupopeg administration in de novo AML patients aged < 55 years with cytogenetics t(15; 17) have not been established.
Consolidation (de novo Ph+ ALL) Study ADE04

This phrase is incorrect in English. The correct form is "de novo" without the preposition "in."

"in de novo"

Show examples from the web [+]

The safety and efficacy of Neulasta administration in de novo AML patients aged < 55 years with cytogenetics t(15; 17) have not been established.
The Committee for Medicinal Products for Human Use (CHMP) decided that Simulect's benefits are greater than its risks for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients.
Simulect is indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation in adult and paediatric patients (1-17 years) (see section 4.2).
Clinical studies The efficacy of basiliximab in prophylaxis of organ rejection in de novo renal transplantation has been demonstrated in double-blind placebo-controlled studies.
Cases of bronchial anastomotic dehiscence, most fatal, have been reported in de novo lung transplant patients when sirolimus has been used as part of an immunosuppressive regimen.
The safety and efficacy of filgrastim administration in de novo AML patients aged < 55 years with good cytogenetics [t(8; 21), t(15; 17), and inv(16)] have not been established.
ed The safety and efficacy of Neupopeg administration in de novo AML patients aged < 55 years with cytogenetics t(15; 17) have not been established.
In de novo kidney and liver transplant patients AUC0-24 of tacrolimus for Advagraf on Day 1 was 30% and 50% lower respectively, when compared with that for Prograf at equivalent doses.
In two clinical studies in de novo liver transplant patients the use of sirolimus plus ciclosporin or tacrolimus was associated with an increase in hepatic artery thrombosis, mostly leading to graft loss or death.
Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including t
greater than its risks for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation, used concomitantly with an immunosuppressive regimen, including ciclosporin and corticosteroids in patients who are not highly immunised.
Paediatrics The pharmacokinetics of basiliximab were assessed in 39 paediatric de novo renal transplantation patients.
The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant recipients.
Limited clinical data suggest a comparable effect on time to recovery of severe neutropenia for pegfilgrastim to filgrastim in patients with de novo acute myeloid leukaemia (see section 5.1).
Results from clinical trials performed with once-daily tacrolimus Advagraf Liver transplantation The efficacy and safety of Advagraf and Prograf, both in combination with corticosteroids, was compared in 471 de novo liver transplant recipients.
Kidney transplantation The efficacy and safety of Advagraf and Prograf, both in combination with mycophenolate mofetil (MMF) and corticosteroids, was compared in 667 de novo kidney transplant recipients.
The efficacy and safety of Prograf, ciclosporin and Advagraf, all in combination with basiliximab antibody induction, MMF and corticosteroids, was compared in 638 de novo kidney transplant
Besides anthropogenic sources, the substance is also expected to be formed de novo in the environment, which does not result from the life-cycle of the substance produced in or imported into the European Community.
One (1) additional low-titre de novo inhibitor was observed.
This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.

How TextRanch works

Fast and reliable proofreading, editing, and language advice tailored to your needs.

1. Choose Your Service

Quick Text Editing

Emails and short texts
Proofreading & editing
Ready in 5-10 minutes

SUBMIT YOUR TEXT NOW

Document Editing

Documents of any type (*.docx)
Advanced & Premium editing
Ready in as little as 4 hours

UPLOAD YOUR DOCUMENT

Ask an Editor

Personalized answers to your language questions
Expert guidance on grammar, style, and usage
Ready in 24 hours

ASK YOUR QUESTION

Upload your document or paste your text directly into our platform. Your text is reviewed and refined by our expert editors (real people, not machines) who understand the nuances of English. Expect corrections, improvements, and insightful suggestions that enhance the clarity, tone, and professionalism of your writing.

3. Receive Your Polished Text

In just a few minutes (or hours for longer documents), you'll receive your corrected text. Review the changes, make any final adjustments, and confidently share your polished English with the world.
You can count on a personalized, friendly service every time you use TextRanch. We're committed to helping you make a great impression with every word you write.

We proofread and edit these types of texts and documents:

Short texts Business Emails Personal Emails Social media posts Resume and Curriculum Vitae Business documents Sales proposal Research and academic papers Thesis Dissertation Essays Articles Blog posts and much more....

Our Customers Love Us!

We have an average rating of 4.79 stars based on 283125 votes, and

4.9 Excellent - Reviews 2.137

"7 years without any disappointment. Always 100% satisfied. You guys are the best in the world at what you do. Thank you so much :)"

Zubair
from Bangladesh

"I wasn't aware of this service, it's fascinating and more reliable than standard IA tools available on the internet"

Arturo
from Mexico

"In a world of text messages and online communication, this is great to have as a live tool. Thank you."

Selena
from USA

"Wow, it's just so excellent. I never would have believed I could have a sure and excellent English companion. Thanks, TextRanch."

Ifiok
from Nigeria

"This is my first time using TextRanch, and I like how the editors take time to correct my text. To everyone who has never used TextRanch before, I highly recommend trying it."

Wilson
from France

"It is an amazing source of feedback because, as a non-native speaker, I really need to have a reliable helper correct my text."

Susan
from Germany

de novo vs in de novo

"de novo"

"in de novo"

Related Comparisons

2. Submit Your Text

3. Receive Your Polished Text